Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

By Matthew E. Falagas, S. Kasiakou. Clinical Infectious Diseases, 2005

1,735 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/448715514d3219c7dfa125fa283942d0fae9ec2d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Molecular Medicine

In Pharmacology

Citations in the corpus

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies (2006, background): “Polymyxin B has the same structure as colistin but contains D-phenylalanine instead of Dleucine [13].”
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “Our therapeutic options for these pathogens are so extremely limited that clinicians are forced to use older, previously discarded drugs, such as colistin, that are associated with significant toxicity and for which there is a lack of robust data to guide selection of dosage regimen or duration of t”
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents (2016, background): “This model suggests that, due to greater affinity for the LPS, AMPs displace the divalent cations and bind to the LPS.”
Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) (2020, background): “Indeed, this suppressing action is still not clear, since the plasma endotoxin immediately bounds by LPS-binding protein, and the complex is quickly bound to cell-surface CD14 [1,28].”
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. (2007, background): “The emergence of infections with multidrug-resistant gram-negative organisms, combined with a paucity of new drug development, has unfortunately led to the resurgent use of colistin, a polymyxin antimicrobial pre viously abandoned because of its high rates of nephrotoxicity and neurotoxicity [43].”
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes (2017, background): “), Gram-positive bacteria, and anaerobic bacteria (13).”
Pharmacokinetic issues for antibiotics in the critically ill patient (2009, background): “This molecule is hydrolyzed to sulfomethylated derivatives and colistin (142).”
The negative impact of antibiotic resistance. (2016, background): “Carbapenem-resistant Acinetobacter baumannii infection [35,36] Less efficacious or more toxic agents Infection with colistin-resistant A.”
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “The drug displays a concentration-dependent bactericidal activity [122] and has recently been re-introduced for the management of pulmonary infections in cystic fibrosis patients, either by the intravenous route or in the form of an aerosol [124], with lower rates of toxicity than reported previousl”
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. (2007, background): “Knowledge on the pharmacology and clinical use of colistin has been reviewed recently.(11,12,15) Since iv polymyxin B has also been increasingly prescribed in many parts of the world, we review recent progress on its PK, PD and clinical experience in this paper.”
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. (2008, background): “Resistance to polymyxins has been reported, possibly as a result of outer cell membrane alterations or an efflux pump mechanism [65, 66, 94, 95].”
Summary of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship (2007, background): “The emergence of infections with multidrug-resistant gram-negative organisms, combined with a paucity of new drug development, has unfortunately led to the resurgent use of colistin, a polymyxin antimicrobial previously abandoned because of its high rates of nephrotoxicity and neurotoxicity [43].”
Phage Therapy in the Postantibiotic Era (2019, background): “The latter is the case for polymyxins and chloramphenicol, which were abandoned due to toxicity concerns (nephrotoxicity/neurotoxicity and rare but potentially fatal hematological side effects, respectively) and are now making a comeback (34, 35).”
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients (2011, background): “With a paucity of new drugs available to treat infections caused by these MDR organisms, colistin, also known as polymyxin E, which was first introduced in the late 1950s, has reemerged as a treatment of choice and often as the only antibiotic active against these organisms (14, 26, 33).”